The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Seminar Title
Keynote 3 – Drug safety in geriatric patients
Affiliation
Helios Klinikum Wuppertal/University Witten/Herdecke
Country
Germany
1. Current Status, Position
- Director of the Philipp Klee-Institute of Clinical Pharmacology at the Helios Klinikum Wuppertal;
- Chair of the Department of Clinical Pharmacology at the University of Witten/Herdecke, Faculty of Health, Department of Medicine.
2. Education
- 1979 -1986: Studies of Medicine, Johann Wolfgang Goethe-University in Frankfurt/Main, Germany
- Dec. 1986 -May 1997: Physician, assistant lecturer, later assistant Professor at the Institute of Clinical Pharmacology (Director: Prof. Dr. N. Rietbrock) at the Johann Wolfgang Goethe-University in Frankfurt/Main, Germany
- 1987: Degree “Doctor of Medicine”(Dr. med.)
- 1992: Consultant in „Clinical Pharmacology“
- 1997: Habilitation and venia legendi (Privat Dozent) in Clinical Pharmacology1997: Habilitation and venia legendi (Privat Dozent) in Clinical Pharmacology
- 1997: Director of the Institute of Clinical Pharmacology at the HELIOS Klinikum Wuppertal
- 1998: Professor and Chair of Clinical Pharmacology at the University of Witten/Herdecke, Germany
3. Research Area
Earlier works, i.e. thesis of doctorate and PhD thesis, were focused on cardiovascular drugs, particularly on the anti-ischaemic effects of ACE-inhibitors, their effects on cardiac function and on small vessel, as well as left ventricular hypertrophy. Being involved in drug research, special emphasis was put on the inclusion and analysis of female participants.
Currently her interest focuses on drug safety, i.e. coordination of the German Network of Pharmacovigilance Centers and other pharmacovigilance activities. This is accomplished by research in Geriatric Clinical Pharmacology, the development of a German list of potentially inappropriate medication (PRISCUS-list) and conduct of intervention studies to improve safer prescribing for elderly patients.